Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection

Next Previous
Trial Profile

Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Traneurocin (Primary) ; Atazanavir; Dexamethasone
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Acronyms NATADEX
  • Sponsors NeuroActiva

Most Recent Events

  • 04 Aug 2022 Trial design, presented at the Alzheimer's Association International Conference 2022
  • 31 Jan 2022 Planned End Date changed from 15 Feb 2021 to 15 Dec 2023.
  • 31 Jan 2022 Planned primary completion date changed from 31 Dec 2020 to 15 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top